Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02808208 · ClinicalTrials.gov registry record · Phase 1
Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure
A Phase 1 study of End Stage Renal Disease (ESRD) and Vascular Access Complication, sponsored by Mayo Clinic.
- Active
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
- 1
- Study location
NCT02808208: Active Phase 1 study of End Stage Renal Disease (ESRD) and Vascular Access Complication, sponsored by Mayo Clinic.
NCT02808208 is a Phase 1 study of End Stage Renal Disease (ESRD) and Vascular Access Complication that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 74 participants, below the 369-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02808208, a Phase 1 study of End Stage Renal Disease (ESRD) and Vascular Access Complication, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this phase 1 study is to determine the role of autologous adipose derived mesenchymal stem cells in the reduction of hemodialysis arteriovenous fistula failure when applied during the time of surgical creation.
Primary Outcome
Diameter of outflow vein by ultrasound
Conditions Studied
Interventions
- DRUG Placebo
- BIOLOGICAL Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)
- BIOLOGICAL Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2017-06-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT02808208 still lists
NCT02808208 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 74 participants, a relatively small participant target, below the 369-participant average among 10 other End Stage Renal Disease (ESRD) trials with a reported enrollment target (80% lower).
The record links to 2 conditions, with End Stage Renal Disease (ESRD) appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02808208 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT02808208 about?
NCT02808208 is a clinical study titled "Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure". The aim of this phase 1 study is to determine the role of autologous adipose derived mesenchymal stem cells in the reduction of hemodialysis arteriovenous fistula failure when applied during the time of surgical creation.
What is the current status of trial NCT02808208?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2017-06-07. Estimated completion is 2026-12.
What conditions does trial NCT02808208 study?
This clinical trial studies the following conditions: End Stage Renal Disease (ESRD), Vascular Access Complication.
What interventions are being tested in trial NCT02808208?
The interventions under investigation include: Placebo (DRUG), Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC) (BIOLOGICAL), Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02808208?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02808208 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for End Stage Renal Disease (ESRD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02808208's enrollment target sits among peer trials
74 7th of 10 higher than 4 of 10 other End Stage Renal Disease (ESRD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other End Stage Renal Disease (ESRD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
ACTIVE NOT RECRUITING · Phase 1
-
Pivotal Study of the Velocity™ pAVF System
RECRUITING · NA
-
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
RECRUITING · Phase 3
-
EndoForce Post Approval Study
RECRUITING
-
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422731 · 74 participants · Early Phase 1
Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy
- NCT03804853 · 74 participants · NA
Rehabilitation Following Reverse Total Shoulder Arthroplasty
- NCT04065776 · 74 participants · NA
Evaluation of Hippocampal-Avoidance Using Proton Therapy in Low-Grade Glioma
- NCT04771156 · 74 participants · Phase 4
Ketorolac in Palatoplasty
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI